Federal Register / Vol. 61, No. 101 / Thursday, May 23, 1996 / Notices 25895

information about Honda or other

manufacturers, the Department would of

course consider it.

Finally, you request the opportunity to

appear before the Court to be heard regarding

the decree’s notification provisions and to

present additional evidence of concerted

activities by automobile dealers and

manufacturers. Under Section 2 of the

Antitrust Procedures and Penalties Act (the

‘‘Tunney Act’’), 15 U.S.C. § 16(b), which

governs proposed final judgments such as

this one, the Court may hold a hearing in

order to make its determination as to whether

the proposed decree is in the public interest,

but is not required to do so. As discussed

above, we believe that the decree fully

redresses the violations alleged in the

complaint and that the addition you propose

to the decree’s notification provisions would

apply to activities not covered by that decree.

Moreover, a Tunney Act hearing is an

inappropriate forum to consider evidence of

alleged concerted conduct that is not

addressed in the complaint. See U.S. v.

Microsoft, 56 F.3d 1448 (D.C. Cir 1995). If

you are aware of any such evidence, we

encourage you to bring it to our attention.

While we do not believe the hearing you

request is appropriate, we will provide a

copy of your letter, along with this response,

to the Court when we file our response to

public comments.

I hope this letter responds to your

concerns. Thank you for your interest in this

matter and in the enforcement of the antitrust

laws.

Sincerely yours,

Mary Jean Moltenbrey,

Chief, Civil Task Force.

[FR Doc. 96–12775 Filed 5–22–96; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 2, 1996, and

published in the Federal Register on

February 13, 1996, (61 FR 5570), Ansys

Inc., 2 Goodyear, Irvine, California

92718, made application to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Cathinone (1235) ......................... I

Methcathinone (1237) .................. I

Heroin (9200) ............................... I

Phencyclidine (7471) .................... II

1-Piperidinocyclohexanecarbonitrile (8603).II

Levorphanol (9220) ...................... II

No comments or objections have been

received. DEA has considered the

factors in 21 U.S.C. 823(a) and

determined that the registration of

Ansys Inc. to manufacture the listed

controlled substances is consistent with

the public interest at this time.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR §§ 0.100 and 0.104, the

Deputy Assistant Administrator, Office

of Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: May 16, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–12971 Filed 5–22–96; 8:45 am]

BILLING CODE 4410–09–M

Importer of Controlled Substances;

Notice of Registration

By Notice dated March 27, 1996, and

published in the Federal Register on

April 4, 1996, (61 FR 15119), Lonza

Riverside, 900 River Road,

Conshohocken, Pennsylvania 19428,

made application to the Drug

Enforcement Administration (DEA) to

be registered as an importer of

phenylacetone (8501), a basic class of

controlled substance listed in Schedule

II.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Lonza Riverside to import

phenylacetone is consistent with the

public interest and with United States

obligations under international treaties,

conventions, or protocols in effect on

May 1, 1971, at this time. Therefore,

pursuant to Section 1008(a) of the

Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations, Section

1311.42, the above firm is granted

registration as an importer of the basic

class of controlled substance listed

above.

Dated: May 16, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–12972 Filed 5–22–96; 8:45 am]

BILLING CODE 4410–09–M

[DEA No. 150P]

Controlled Substances: Notice of

Proposed 1996 Aggregate Production

Quotas

AGENCY: Drug Enforcement

Administration, Justice.

ACTION: Notice of proposed revised

aggregate production quotas for 1996.

SUMMARY: This notice proposes revised

1996 aggregate production quotas for

controlled substances in Schedules I

and II, as required under the Controlled

Substances Act of 1970.

DATES: Comments or objections should

be received on or before June 24, 1996.

ADDRESSES: Send comments or

objections to the Administrator, Drug

Enforcement Administration,

Washington, D.C. 20537, Attn: DEA

Federal Register Representative/CCR.

FOR FURTHER INFORMATION CONTACT:

Howard McClain, Jr., Chief, Drug &

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, D.C. 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the Controlled Substances Act

(CSA) (21 U.S.C. 826) requires that the

Attorney General establish aggregate

production quotas for all controlled

substances listed in Schedules I and II.

This responsibility has been delegated

to the Administrator of the DEA

pursuant to § 0.100 of Title 28 of the

Code of Federal Regulations. The

Administrator, in turn, has redelegated

this function to the Deputy

Administrator of the DEA by section

0.104 of Title 28 of the Code of Federal

Regulations.

On November 21, 1995, a notice of the

1996 established aggregate production

quotas was published in the Federal

Register (60 FR 57808). The notice

stipulated that the Deputy

Administrator of the DEA would adjust

the quotas in early 1996 as provided for

in Title 21, Code of Federal Regulations,

Section 1303.23(c). Subsequently, the

DEA revised 1996 aggregate production

quotas for amobarbital, heroin and

hydromorphone as published in the

Federal Register (61 FR 19090 and 61

FR 14336). Those revised figures are

included with the proposed 1996

revised aggregate production quotas

below. These proposed aggregate

production quotas represent those

amounts of controlled substances that

may be produced in the United States in

1996 and do not include amounts which

may be imported for use in industrial

processes.

The proposed revisions are based on

a review of 1995 year-end inventories,

1995 disposition data submitted by

quota applicants, estimates of the

medical needs of the United States

submitted to the DEA by the Food and

Drug Administration and other

information available to the DEA.
25896 Federal Register / Vol. 61, No. 101 / Thursday, May 23, 1996 / Notices

Therefore, under the authority vested

in the Attorney General by section 306

of the CSA of 1970 (21 U.S.C. 826),

delegated to the Administrator by

Section 0.100 of Title 28 of the Code of

Federal Regulations, and redelegated to

the Deputy Administrator by Section

0.104 of Title 28 of the Code of Federal

Regulations, the Deputy Administrator

of the DEA hereby proposes the

following 1996 aggregate production

quotas for the listed controlled

substances, expressed in grams of

anhydrous acid or base.

Basic class Previously established 1996

aggregate production quotas

Proposed revised 1996 aggregate production quotas

Schedule I:

Acetylmethadol .................................................................................................. 7 7

Alphacetylmethadol ........................................................................................... 7 7

Aminorex ........................................................................................................... 7 7

Cathinone .......................................................................................................... 9 9

Difenoxin ........................................................................................................... 14,000 14,000

Dihydromorphine ............................................................................................... 7 7

2, 5-Dimethoxyamphetamine ............................................................................ 10,650,000 10,650,000

Dimethylamphetamine ...................................................................................... 7 7

Ethylamine analog of Phencyclidine ................................................................. 5 5

N-Ethylamphetamine ......................................................................................... 7 7

Heroin ................................................................................................................ 5 5

Lysergic acid diethylamide ................................................................................ 58 58

Mescaline .......................................................................................................... 7 7

Methaqualone ................................................................................................... 17 17

Methcathinone ................................................................................................... 9 9

4-Methoxyamphetamine .................................................................................... 17 17

4-Methylaminorex .............................................................................................. 2 2

3,4-Methylenedioxyamphetamine ..................................................................... 17 17

3,4-Methylenedioxy-N-ethylamphetamine ......................................................... 27 27

3,4-Methylenedioxymethamphetamine ............................................................. 42 42

3-Methylfentanyl ................................................................................................ 14 14

Normethadone .................................................................................................. 7 7

Normorphine ..................................................................................................... 7 7

Psilocybin .......................................................................................................... 2 2

Psilocyn ............................................................................................................. 2 2

Tetrahydrocannabinols ...................................................................................... 55,100 55,100

Schedule II:

Alfentanil ........................................................................................................... 8,500 8,500

Amobarbital ....................................................................................................... 301,000 301,000

Amphetamine .................................................................................................... 1,863,200 2,280,000

Cocaine ............................................................................................................. 550,040 550,040

Codeine (for sale) ............................................................................................. 58,395,000 47,000,000

Codeine (for conversion) .................................................................................. 16,632,000 17,519,000

Desoxyephedrine .............................................................................................. 1,044,000 1,044,000

(1,000,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product and 44,000 grams for methamphetamine)

Dextropropoxyphene ......................................................................................... 118,066,000 118,066,000

Dihydrocodeine ................................................................................................. 116,000 214,000

Diphenoxylate ................................................................................................... 1,063,000 1,002,000

Ecgonine (for conversion) ................................................................................. 650,100 650,100

Ethylmorphine ................................................................................................... 12 12

Fentanyl ............................................................................................................ 120,100 143,000

Hydrocodone (for sale) ..................................................................................... 10,575,000 12,145,000

Hydrocodone (for conversion) .......................................................................... 2,800,000 2,800,000

Hydromorphone ................................................................................................ 718,000 718,000

Isomethadone ................................................................................................... 12 12

Levo-alpha-acetylmethadol ............................................................................... 200,000 200,000

Levorphanol ...................................................................................................... 14,300 14,300

Meperidine ........................................................................................................ 10,822,000 10,822,000

Methadone ........................................................................................................ 4,551,000 4,551,000

Methadone (for conv) ........................................................................................ 364,000 364,000

Methadone Int. (for conv) ................................................................................. 5,534,000 5,534,000

Methamphetamine (for conv) ............................................................................ 723,000 723,000

Methylphenidate ................................................................................................ 10,291,000 11,090,000

Morphine (for sale) ............................................................................................ 12,450,000 12,450,000

Morphine (for conv) ........................................................................................... 76,735,000 76,735,000

Noroxymorphone (for sale) ............................................................................... 2,000 2,000

Noroxymorphone (for conv) .............................................................................. 3,400,000 3,400,000

Opium ................................................................................................................ 1,226,000 714,000

Oxycodone (for sale) ........................................................................................ 5,571,000 5,571,000

Oxycodone (for conv) ....................................................................................... 37,300 37,300

Oxymorphone .................................................................................................... 11,200 11,200

Pentobarbital ..................................................................................................... 15,100,000 15,100,000

Phencyclidine .................................................................................................... 40 40

Phenylacetone (for conv) .................................................................................. 5,280,000 10

1-Phenylcyclohexylamine .................................................................................. 10 10
Federal Register / Vol. 61, No. 101 / Thursday, May 23, 1996 / Notices 25897

Basic class Previously established 1996

aggregate production quotas

Proposed revised 1996 aggregate production quotas

1-Piperidinocyclohexanecarbonitrile ................................................................. 12 12

Secobarbital ...................................................................................................... 400,000 400,000

Sufentanil .......................................................................................................... 1,000 1,000

Thebaine ........................................................................................................... 9,217,000 9,387,000

All interested persons are invited to

submit their comments and objections

in writing regarding this proposal. A

person may object to or comment on the

proposal relating to any of the above

mentioned substances without filing

comments or objections regarding the

others. If a person believes that one or

more of these issues warrant a hearing,

the individual should so state and

summarize the reasons for this belief.

In the event that comments or

objections to this proposal raise one or

more issues which the Deputy

Administrator finds warrant a hearing,

the Deputy Administrator shall order a

public hearing by notice in the Federal

Register, summarizing the issues to be

heard and setting the time for the

hearing.

The Office of Management and Budget

has determined that notice of aggregate

production quotas are not subject to

centralized review under Executive

Order 12866.

Rules establishing aggregate

production quotas for controlled

substances in Schedules I and II are

required by statute, fulfill United States

obligations under the Single Convention

on Narcotic Drugs, 1961, and other

international treaties, and are essential

to a criminal law enforcement function

of the United States. Without the

periodic establishment and adjustment

of aggregate production quotas,

pharmaceutical manufacturers in the

United States could not lawfully

produce a wide variety of medically

necessary pharmaceutical drugs.

These actions have been analyzed in

accordance with the principles and

criteria contained in Executive Order

12612 and it has been determined that

this matter raises no Federalism

implications which would warrant the

preparation of a Federalism Assessment.

The Deputy Administrator hereby

certifies that this action will have no

significant impact upon small entities

whose interests must be considered

under the Regulatory Flexibility Act, 5

U.S.C. 601, et seq. The establishment

and revision of annual production

quotas for Schedules I and II controlled

substances is mandated by law and by

the international obligations of the

United States. Such quotas impact

predominantly upon major

manufacturers of the affected controlled

substances.

Dated: May 15, 1996.

Stephen H. Greene,

Deputy Administrator.

[FR Doc. 96–12899 Filed 5–22–96; 8:45 am]

BILLING CODE 4410–09–M

Foreign Claims Settlement

Commission

Registration of Potential Claims

Against Iraq

AGENCY: Foreign Claims Settlement

Commission; Justice.

ACTION: Notice.

SUMMARY: The Foreign Claims

Settlement Commission announces the

establishment of an Iraq Claims

Registration Program for registration of

potential claims of United States

nationals (individuals U.S. citizens,

corporations and other legal entities)

against the Government of Iraq.

DATES: The deadline for registration of

claims is June 28, 1996.

FOR FURTHER INFORMATION CONTACT:

David E. Bradley, Chief Counsel,

Foreign Claims Settlement Commission

of the United States, 600 E Street, N.W.,

Suite 6002, Washington, DC 20579. Tel.

(202) 616–6975; FAX (202) 616–6993.

Notice of Commencement of Claims

Registration Program, and of Program

Completion Date

This year marks the fifth anniversary

of the Persian Gulf War. As a result of

that conflict and related events,

thousands of United States nationals

(individual U.S. citizens, corporations

and other legal entities) suffered

injuries, losses and damages. Many

claims arising directly out of Iraq’s

invasion and occupation of Kuwait are

being heard by the United States

Compensation Commission (‘‘UNCC’’)

in Geneva. However, at present there is

no viable forum for the estimated $5

billion in outstanding claims against

Iraq which fall outside the UNCC’s

jurisdiction (‘‘non-UNCCC claims’’).

The Foreign Claims Settlement

Commission of the United States

(FCSC), an independent, quasi-judicial

agency within the U.S. Department of

Justice, has begun a program for United

States nationals (private citizens,

corporations, and other legal entities) to

register these non-UNCC claims against

the Government of Iraq for breach of

contract, loss of and damage to property,

physical injury or illness, and other

losses and damages.

Claims to be registered in this

program are claims against the

Government of Iraq (and its

subdivisions and controlled entities)

that are not within the UNCC’s

jurisdiction. The UNCC’s jurisdiction is

defined by relevant United Nations

Security Council resolutions

(particularly 687 and 692) and the

decisions of the UNCC Governing

Council.

The claims covered by this

Registration Program include: (1) All

claims which arose prior to Iraq’s

August 2, 1990, invasion of Kuwait; (2)

all claims of U.S. military personnel or

their survivors which arose out of Desert

Shield and Desert Storm (other than

claims for inhumane treatment of

prisoners of war, which are

compensable by the UNCC); and (3) all

claims arising out of Iraq’s 1987 attack

on the U.S.S. Stark (other than wrongful

death claims, which have been

compensated by Iraq).

The information collected in the

FCSC Iraq Claims Registration Program

will be used to compile an accurate and

comprehensive Registry of claimants

and claims against Iraq, in preparation

for the adjudication of those claims

upon enactment of authorizing

legislation. If such legislation is not

enacted, the information will be used to

ensure that all claims are taken into

account in connection with any future

claims settlement negotiations with Iraq.

This Claims Registration Program will

update and supplement the information

on such claims compiled by the

Treasury Department in 1991. (56 FR

5636, Feb. 11, 1991) Potential claimants

who registered previously with the

Treasury Department should also file in

this new Registration Program.

Requests for claim registration forms

should be directed to the following

address: Foreign Claims Settlement

Commission, Attn: Iraq Claims

Registration, Washington, DC 20579.

Forms also may be requested in

person at the offices of the Foreign

Claims Settlement Commission, 600 E